State of New Jersey Common Pension Fund D Has $1.27 Million Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

State of New Jersey Common Pension Fund D trimmed its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 9.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,580 shares of the biopharmaceutical company’s stock after selling 4,013 shares during the quarter. State of New Jersey Common Pension Fund D owned approximately 0.07% of Agios Pharmaceuticals worth $1,268,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in AGIO. Wingate Wealth Advisors Inc. bought a new position in Agios Pharmaceuticals during the 4th quarter worth approximately $53,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 363 shares during the period. Quest Partners LLC boosted its position in Agios Pharmaceuticals by 139.6% during the third quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 1,283 shares during the last quarter. KBC Group NV grew its holdings in Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 611 shares during the period. Finally, Quantbot Technologies LP bought a new position in shares of Agios Pharmaceuticals in the 3rd quarter worth about $146,000.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Trading Down 0.8 %

AGIO opened at $35.19 on Wednesday. The company has a market cap of $2.02 billion, a price-to-earnings ratio of 3.10 and a beta of 0.88. The company’s fifty day moving average price is $34.01 and its two-hundred day moving average price is $42.92. Agios Pharmaceuticals, Inc. has a 1-year low of $27.14 and a 1-year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, equities analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on AGIO. Royal Bank of Canada upped their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Scotiabank lifted their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Finally, HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a report on Monday. They issued a “buy” rating and a $58.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $56.57.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.